Monitor for Phase 1 data from SEP-479 trial in late 2026/early 2027, which could be a catalyst for the stock. The company's cash runway into 2029 provides runway for clinical development, but no immediate financial impact from this announcement.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $23.34entry
- T+1 · 7mo ago +3.38%α +2.17% · $24.13
- T+5 · 7mo ago +15.08%α +11.79% · $26.86
- T+20 · 6mo ago +0.99%α −6.74% · $23.57
- T+60 · 4mo ago +55.96%α +47.03% · $36.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna announced the initiation of Phase 1 clinical trials for its oral PTH1R agonist SEP-479 for hypoparathyroidism, with data expected in late 2026 or early 2027. The company also provided updates on its other clinical programs including SEP-631 and its collaboration with Novo Nordisk, while highlighting its cash runway into 2029.
Key Facts
- Company initiated Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism
- Phase 1 trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers
- Data from the trial is anticipated in late 2026 or early 2027
- SEP-631 Phase 1 study demonstrated robust pharmacodynamics with QD dosing
- Company plans to initiate Phase 2b trial in chronic spontaneous urticaria in 2H 2026
- Cash runway expected to support operating plans at least into 2029
- Company has a $195M upfront payment from Novo Nordisk collaboration
Financial Impact
No immediate financial impact disclosed, but advancement of clinical programs could impact future revenue potential
Risk Factors
- Clinical trial results may not meet expectations
- Development timelines may be delayed
- Competition in hypoparathyroidism and urticaria markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152045 |
| Document: d57504d8k.htm | 0001193125-26-152045 |
| Document: d57504dex991.htm | 0001193125-26-152045 |
| Document: 0001193125-26-152045-index-headers.html | 0001193125-26-152045 |
| Document: 0001193125-26-152045-index.html | 0001193125-26-152045 |
| Document: 0001193125-26-152045.txt | 0001193125-26-152045 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $41.67 +20.39% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers